← boardnext 2028-03
HALO
Halozyme Therapeuticsdistress 2/10 · well-funded / low risk$77.90+0%today-4% from 52w high
Lead: Hypogonadism
Revenue
$377M
Liquidity
$310M
Runway
—
Shares 1y
+1%
Price & events
+9.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.1%
1D
+0.5%
1W
+11.9%
1M
+17.0%
3M
+12.5%
6M
+33.0%
1Y
+40.6%
2Y
+81.6%
5Y
+83.7%
All
Overview
- Market Cap
- $9.24B
- Enterprise Value
- $10.87B
- Volume
- 68.64K
- 52 Week Range
- $55.92 – $81.57
- Total Shares
- 118.61M
- Float Shares
- 117.25M
- Short %
- 14.42%
- % Held by Insiders
- 1.07%
- % Held by Institutions
- 108.51%
- RVOL
- 0.04x
- Beta
- 0.84
Pipeline stages · 1 programs
Testosterone enanthate
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-03 Estimated 50% readout ~2028-05-15 | Phase 3 | Testosterone enanthate | Hypogonadism, Male | — | recruiting |
Catalyst news & presentations · 3
- by year end 2026Guided 40%trial initiationsecondaryHypercon formulated product · Two of Elektrofi's partners projected to begin Hypercon formulated product clinical developmentSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-09-30partnershipHypercon technology · Halozyme acquires Elektrofi for $750M upfront and up to $150M milestonesSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $84 (+8% upside) · 10 analysts
- 2026-07-21HC Wainwright & Co.Buy
- 2026-05-12Morgan StanleyOverweight
- 2026-04-29HC Wainwright & Co.Buy
- 2026-02-19BenchmarkBuy
- 2026-02-19Wells FargoEqual-Weight
- 2026-01-08TD CowenBuy
Competitors — Hypogonadism
- none identified
Recent news
- 2026-07-23Halozyme to Report Second Quarter 2026 Financial and Operating Results - Yahoo Finance
- 2026-07-22Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued - Sahm
- 2026-07-22Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs - FXEmpire
- 2026-07-21Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com - Investing.com Nigeria
- 2026-07-21Benchmark reiterates Halozyme stock Buy rating on Incyte deal - Investing.com
- 2026-07-21HALO Inks Deal With INCY to Support Cancer Therapy Development - Yahoo Finance
- 2026-07-21Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com - Investing.com Canada
- 2026-07-21HALO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.